| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V39212-1mg |
≥99% | ￥1980.00 |
货期：3-5天 | - | - | - | - |
|
V39212-2mg |
≥99% | ￥2970.00 |
货期：3-5天 | - | - | - | - |
|
V39212-5mg |
≥99% | ￥4920.00 |
货期：3-5天 | - | - | - | - |
|
V39212-10mg |
≥99% | ￥7130.00 |
货期：3-5天 | - | - | - | - |
|
V39212-25mg |
≥99% | ￥10600.00 |
货期：3-5天 | - | - | - | - |
|
V39212-50mg |
≥99% | ￥13800.00 |
货期：3-5天 | - | - | - | - |
|
| 体内研究： | MBC-11 (0.04 μg/day, s.c.) has a lower incidence of bone metastases of 40% compared to those treated with PBS (90%) or 0.04 μg/day zoledronate (100%). MBC-11 also significantly decreases bone tumor burden compared to PBS- or zoledronate-treated mice. Weight gained in mice treated with up to 500 μg/day of MBC-11 is similar to the PBS treated group. These results demonstrate that MBC-11 decreases bone tumor burden, maintains bone structure, and may increase overall survival, warranting further investigation as a treatment for tumor-induced bone disease (TIBD). |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京